On Thursday, in the course of current trade, Shares of Opko Health Inc. (NYSE:OPK), dropped -2.72%, and is now trading at $11.08.
OPKO Health, released the following open letter from Phillip Frost, M.D., its Chairman and Chief Executive Officer, to its shareholders:
Dear Shareholder,
I want to take the occasion of OPKO’s recently declared acquisition of Bio-Reference Laboratories (Bio-Reference) to present a general overview of the company’s present activities. They are many and while, in some respects, they differ greatly from one another, all share a common theme. They all deal with products for large markets in which OPKO has an opportunity to be a leader, and all have potential for long-term growth. We hope to achieve this growth by providing an ever increasing spectrum of medicines and tests, some new and novel, others of already established value, to assist physicians provide better care for their patients.
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally.
During an Afternoon trade, Shares of Insys Therapeutics Inc (NASDAQ:INSY), dipped -0.91%, and is now trading at $32.54.
Insys Therapeutics, declared it has filed a Citizen Petition with the Drug Enforcement Administration (“DEA”) to request the agency replan its synthetic pharmaceutical cannabidiol (“CBD”) from Plan I to Plan IV. The Company believes that the current classification of synthetic CBD as a Plan I compound is a noteworthybarrier to the progress of research studies that explore the value of this compound in the treatment of several serious medical conditions.
“CBD is a non-psychoactive compound found in the marijuana plant that offers the potential to provide a treatment option to patients suffering from a wide variety of diseases,” said Steve Sherman, Vice President, Regulatory Affairs, at Insys Therapeutics. “Importantly, Insys’s synthetic pharmaceutical CBD is a form of the compound that is identical in chemical structure to naturally-occurring CBD, but because it is not derived from marijuana, it is free of THC and other cannabinoid impurities, ensuring a compriseent and controlled dosage with little or no potential for abuse.”
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Finally, Affymetrix, Inc. (NASDAQ:AFFX), gained 2.92% Thursday.
Affymetrix, declared that equity awards were made to 13 new non-executive officer employees as inducement to join Affymetrix. The equity awards were granted following NASDAQ Marketplace Rule 5635(c)(4) under the Affymetrix, Inc. 2012 Inducement Plan, which the Board of Directors of Affymetrix adopted for the granting of inducement equity awards to new employees.
13 employees were granted a combination of Restricted Stock Units (RSUs) and Stock Options to purchase an aggregate of 60,244 shares of the Company’s common stock; 32,000 of the shares granted were Stock Options and 28,244 of the shares granted were RSUs. Both the RSUs and Stock Options vest in equal annual installments over four years. The Stock Options have a maximum term of 7 years.
Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
